BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Viking Therapeutics Stock Plummets 40% Despite Positive Clinical Trial Results
Viking Therapeutics Stock Plummets 40% Despite Positive Clinical Trial Results
23
1
BTCCSquare news:
Viking Therapeutics (VKTX) shares tumbled 40% on Tuesday despite reporting positive Phase 2 data for its metabolic disorder drug VK2735. The dual GLP-1/GIP receptor agonist showed significant weight loss results, with 80% of trial participants achieving over 10% reduction—far exceeding placebo outcomes.
CEO Brian Lian emphasized the drug's potential for long-term weight maintenance, citing progressive efficacy curves. However, investor concerns surfaced around the 20% discontinuation rate due to adverse events, nearly double the placebo group's figure.
By:
